TY - JOUR T1 - 121 Systemic immune-inflammatory index (SII) as a prognostic factor for cervical cancer recurrence JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - A54 LP - A55 DO - 10.1136/ijgc-2020-IGCS.103 VL - 30 IS - Suppl 3 AU - A De Guzman AU - K Baldivia AU - GM Facun AU - C Zalameda - Castro Y1 - 2020/11/01 UR - http://ijgc.bmj.com/content/30/Suppl_3/A54.3.abstract N2 - Objectives Numerous studies on inflammatory hematologic markers have been published in relation to cancer survival and progression, but only two publications have studied the Systemic Immune-Inflammatory Index (SII) among cervical cancer patients. This study aims to validate the cut-off presented by Huang et al., (2019) in his study on cervical cancer and the prognostic ability of the Systemic Immune-Inflammatory Index (SII).Methodology Data from 140 patients diagnosed with cervical cancer recurrence and those without evidence of disease post-treatment were collected retrospectively. The SII, Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Monocyte-Lymphocyte Ratio were all evaluated.Results Based on our univariate Cox Hazard Analysis, bulky tumor (>4 cm) and FIGO stages II and III were prognosticators of worse Progression Free Survival (PFS). Regarding SII, there appears to be an increased likelihood of disease recurrence among women with SII greater than 475 when controlling for the binary classification of the SII (HR: 1.88 (0.96–3.69), p: 0.07). However, this association may be diluted when other variables aside from the SII are accounted for in determining the likelihood of the outcome. On multivariate analysis, only FIGO stage was seen as an independent factor for PFS.Conclusion Based on the sample population, the cut-off values of Huang et al. (2019) of 475 for the SII, 2.4 for NLR, 118 for PLR and 0.26 for MLR were not found to be associated with cervical recurrence by multivariate analysis. Our results support the report of Holub & Biete (2019). Larger, local prospective studies is recommended. ER -